From: Metformin: an old but still the best treatment for type 2 diabetes
Study | Design | Duration | Key findings |
---|---|---|---|
UKPDS 33 [18] | Prospective | 10 yr | Significant reduction in all-cause mortality, diabetes related mortality, and any end-point related to diabetes. |
Sgambato et al.[72] | Retrospective | 3 yr | Trend towards reduction in angina symptoms (p = 0.051). Significant lower re-infarction rates. |
Johnson et al.[24] | Retrospective | 9 yr | Reduction of all-cause mortality and of cardiovascular mortality |
Kao et al.[74] | Prospective | 2 yr | Significant risk reduction for any clinical event, myocardial infarction and all-cause mortality |
Jadhav et al.[76] | Prospective | 8 weeks | Improved maximal ST depression, Duke score, and chest pain incidence |
Kooy et al.[75] | Prospective | 4, 3 yr | Reduction of the risk of developing macrovascular disease |